In-vitro inhibition of biofilm formation in candida albicans and candida tropicalis by heat stable compounds in culture filtrate of aspergillus flavus

Journal of Clinical and Diagnostic Research

Volumn 7, Issue 10, 2013, Pages 2167-2169

  Bhattacharyya, Sayan ^a   Gupta, Prashant ^a   Banerjee, Gopa ^a   Jain, Amita ^a   Singh, Mastan ^a  

^a KING GEORGE'S MEDICAL UNIVERSITY   (India)

Author keywords

Aspergillus flavus; Biofilm; Candida spp; Invasive candidiasis

Indexed keywords

NATURAL PRODUCT; ORGANOHALOGEN DERIVATIVE; TRIACYLGLYCEROL LIPASE;

ARTICLE; ASPERGILLUS FLAVUS; BACTERIAL SURVIVAL; BACTERIUM ISOLATE; BIOFILM; CANDIDA ALBICANS; CANDIDA TROPICALIS; CELL LINE; CONTROLLED STUDY; CYTOTOXICITY; ENZYME ACTIVITY; ENZYME INHIBITION; FUNGUS CULTURE; HEP 2 CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; INFECTION PREVENTION; INVASIVE CANDIDIASIS; LIQUID CULTURE; MICROTITER PLATE ASSAY; OBSERVATIONAL STUDY; THERMOSTABILITY;

EID: 84885226069     PISSN: 2249782X     EISSN: 0973709X     Source Type: Journal    
DOI: 10.7860/JCDR/2013/6020.3460     Document Type: Article

References (22)

1. Lewis RE. Overview of the changing epidemiology of candidemia. Curr Med Res Opin. 2009; 25:1732-40.
2. Farroqi JQ, Jabeen K, Saeed N, Iqbal N, Malik B, Lockhart S, et al. Invasive Candidiasis in Pakistan: Clinical characteristics, species distribution and antifungal susceptibility. J Med Microbiol. 2013 62:259-68.
3. Sardi JC, Scorzoni L, Bernardi T, Fusco-Almeida AM, Mendes Giannini MJ. Candida species: current epidemiology, pathogenicity, biofilm formation, natural antifungal products and new therapeutic options. J Med Microbiol. 2013; 62(1):10-24.
4. Wilke MH. Treatment and Prophylaxis of Invasive candidiasis with Anidulafungin, Caspofungin and Micafungin and its impact on Use and costs-Review of the literature. Eur J Med Res. 2011;16: 180-86.
5. Al-Fattani MA, Douglas LJ. Penetration of Candida Biofilms by Antifungal Agents. Antimicrob. Agents Chemother. 2004; 48: 3291-97.
6. Kanafani ZA, Perfect JR. Resistance to Antifungal Agents: Mechanisms and Clinical Impact. Clin Inf Dis. 2008; 46:120-8.
7. Klausmeyer P, Mc Cloud TG, Tucker KD, Cardellina JH, Shoemaker RH. Aspirochlorine Class Compounds from Aspergillus flavus Inhibit Azole-Resistant Candida albicans. J. Nat. Prod. 2005; 68:1300-02.
8. Gacser A, Stehr F, Kroger C, Kredics L, Schafer W, Nosanchuk JD. Lipase 8 Affects the Pathogenesis of Candida albicans. Infect Immun. 2007;75: 4710-18.
9. Bhattacharyya S, Gupta P, Banerjee G, Jain A, Singh M. Inhibition of Candida biofilms by Pyocyanin: an in-vitro study. Int J Curr Res Rev. 2013;5:31-36.
10. Raju SB, Rajappa S. Isolation and Identification of Candida from the Oral Cavity. ISRN Dentistry. 2011.
11. Ramage G, Walle KV, Wickes BL, Lopez-Ribot JL. Standardized method for in-vitro antifungal susceptibility testing of Candida albicans biofilms. Antimicrobial Agents Chemother.; 45:2475-79.
12. Muhsin TM, Aubaid AH, Al-Duboon AH. Extracellular enzyme activities of dermatophytes and yeast isolates on solid media. Mycoses. 1997; 40: 465-69.
13. th ed New Delhi. Jaypee Brothers Medical Publishers. (P) Ltd.2010.
14. Pfaller MA, Diekema DJ. Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem. Clin Microbiol Rev. 2007; 20: 133-63.
15. Chowta MN, Adhikary P, Rajeev A, Shenoy AK. Study of risk factors and prevalence of invasive candidiasis in a tertiary care hospital. Indian J Crit Care Med. 2007;11:67-73.
16. Bouza E, Munoz P. Epidemiology of candidemia in intensive care units. Int J Antimicrob Agents. 2008;32 Suppl 2:S87-91.
17. Lincoln NJ, Andes MKD. Beta -1,3 glucan as a test for central venous catheter biofilm infection. J Infect Dis. 2007;195:1705.
18. Luber AD, Maa L, Lam M, Guglielmo BJ. Risk factors for Amphotericin B- induced nephrotoxicity. J Antimicrob Chemother. 1999;43: 267-71.
19. Chatzimoschou A, Katragkou A, Simitsopoulou M, Antachopoulos C, Georgiadou E, Walsh TJ, et al. Activities of Triazole-Echinocandin Combinations against Candida Species in Biofilms and as Planktonic Cells. Antimicrob Agents Chemother. 2011;55:1968-74.
20. Grover ND. Echinocandins: A ray of hope in antifungal drug therapy. Indian J Pharmacol. 2010; 42: 9-11.
21. Chen SC, Joosten LAB, Kullberg BJ, Netea MG. Interplay between Candida albicans and the Mammalian Innate Host Defense. Infect Immun. 2012;80: 1304-13.
22. Monti F, Ripamonti F, Hawser SP, Islam K. Aspirochlorine: a highly selective and potent inhibitor of fungal protein synthesis. J Antibiotics. 1999;52:311-8.